JP2020506727A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020506727A5 JP2020506727A5 JP2019563679A JP2019563679A JP2020506727A5 JP 2020506727 A5 JP2020506727 A5 JP 2020506727A5 JP 2019563679 A JP2019563679 A JP 2019563679A JP 2019563679 A JP2019563679 A JP 2019563679A JP 2020506727 A5 JP2020506727 A5 JP 2020506727A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- chimeric protein
- receptor
- mutations
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020001507 fusion proteins Proteins 0.000 claims description 45
- 102000037865 fusion proteins Human genes 0.000 claims description 45
- 230000011664 signaling Effects 0.000 claims description 23
- 230000035772 mutation Effects 0.000 claims description 22
- 102000005962 receptors Human genes 0.000 claims description 22
- 108020003175 receptors Proteins 0.000 claims description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 230000008685 targeting Effects 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 16
- 239000000427 antigen Substances 0.000 claims description 7
- 108091007433 antigens Proteins 0.000 claims description 7
- 102000036639 antigens Human genes 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 101000959794 Homo sapiens Interferon alpha-2 Proteins 0.000 claims description 5
- 108010050904 Interferons Proteins 0.000 claims description 5
- 102000014150 Interferons Human genes 0.000 claims description 5
- 229940079322 interferon Drugs 0.000 claims description 5
- 206010014733 Endometrial cancer Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 230000002238 attenuated effect Effects 0.000 claims description 4
- 210000002865 immune cell Anatomy 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 230000019491 signal transduction Effects 0.000 claims description 4
- 102220492437 2'-5'-oligoadenylate synthase 3_R33A_mutation Human genes 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 239000000556 agonist Substances 0.000 claims description 3
- 239000005557 antagonist Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 210000002540 macrophage Anatomy 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 108091023037 Aptamer Proteins 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 2
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 2
- 206010061692 Benign muscle neoplasm Diseases 0.000 claims description 2
- 206010004593 Bile duct cancer Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 241000251730 Chondrichthyes Species 0.000 claims description 2
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 2
- 201000004458 Myoma Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- -1 adnectins Proteins 0.000 claims description 2
- 230000033115 angiogenesis Effects 0.000 claims description 2
- 229930193936 anticarin Natural products 0.000 claims description 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 2
- 201000000220 brain stem cancer Diseases 0.000 claims description 2
- 201000007455 central nervous system cancer Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 210000004443 dendritic cell Anatomy 0.000 claims description 2
- 230000008030 elimination Effects 0.000 claims description 2
- 238000003379 elimination reaction Methods 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 208000024519 eye neoplasm Diseases 0.000 claims description 2
- 210000002768 hair cell Anatomy 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 208000020082 intraepithelial neoplasia Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 210000001616 monocyte Anatomy 0.000 claims description 2
- 208000025113 myeloid leukemia Diseases 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 201000008106 ocular cancer Diseases 0.000 claims description 2
- 210000004798 organs belonging to the digestive system Anatomy 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000002628 peritoneum cancer Diseases 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 230000000241 respiratory effect Effects 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 230000002485 urinary effect Effects 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 239000000816 peptidomimetic Substances 0.000 claims 1
- 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 10
- 238000000034 method Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102100033808 Glycoprotein hormone alpha-2 Human genes 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101001069261 Homo sapiens Glycoprotein hormone alpha-2 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 101710150912 Myc protein Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 201000001268 lymphoproliferative syndrome Diseases 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 210000003757 neuroblast Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022165861A JP7605800B2 (ja) | 2017-02-06 | 2022-10-14 | 標的化キメラタンパク質及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762454993P | 2017-02-06 | 2017-02-06 | |
| US62/454,993 | 2017-02-06 | ||
| PCT/EP2018/052814 WO2018141964A1 (en) | 2017-02-06 | 2018-02-05 | Targeted chimeric proteins and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022165861A Division JP7605800B2 (ja) | 2017-02-06 | 2022-10-14 | 標的化キメラタンパク質及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020506727A JP2020506727A (ja) | 2020-03-05 |
| JP2020506727A5 true JP2020506727A5 (enExample) | 2021-03-18 |
| JP7476467B2 JP7476467B2 (ja) | 2024-05-01 |
Family
ID=61274224
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563679A Active JP7476467B2 (ja) | 2017-02-06 | 2018-02-05 | 標的化キメラタンパク質及びその使用 |
| JP2022165861A Active JP7605800B2 (ja) | 2017-02-06 | 2022-10-14 | 標的化キメラタンパク質及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022165861A Active JP7605800B2 (ja) | 2017-02-06 | 2022-10-14 | 標的化キメラタンパク質及びその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11384154B2 (enExample) |
| EP (1) | EP3577133A1 (enExample) |
| JP (2) | JP7476467B2 (enExample) |
| KR (1) | KR102642385B1 (enExample) |
| CN (1) | CN110546160A (enExample) |
| AU (1) | AU2018216032B2 (enExample) |
| CA (1) | CA3052523A1 (enExample) |
| IL (1) | IL268346B2 (enExample) |
| MX (1) | MX2019009255A (enExample) |
| WO (1) | WO2018141964A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11753463B2 (en) * | 2016-05-13 | 2023-09-12 | Orionis Biosciences BV | Therapeutic targeting of non-cellular structures |
| MX2019009255A (es) * | 2017-02-06 | 2019-11-05 | Orionis Biosciences Nv | Proteínas quiméricas dirigidas y sus usos. |
| WO2019032661A1 (en) | 2017-08-09 | 2019-02-14 | Orionis Biosciences Inc. | CD8 LIAISON AGENTS |
| JP7423511B2 (ja) | 2017-08-09 | 2024-01-29 | オリオンズ バイオサイエンス インコーポレイテッド | Ｐｄ－１およびｐｄ－ｌ１結合物質 |
| BR112020002706A2 (pt) | 2017-08-09 | 2020-08-25 | Orionis Biosciences Inc. | agentes de ligação a clec9a e uso dos mesmos |
| CN112074267B (zh) | 2018-02-05 | 2024-06-28 | 奥里尼斯生物科学公司股份有限公司 | 成纤维细胞结合剂及其用途 |
| US12084497B2 (en) | 2018-08-08 | 2024-09-10 | Orionis Biosciences, Inc. | SIRP1α targeted chimeric proteins and uses thereof |
| KR20210070307A (ko) * | 2018-10-02 | 2021-06-14 | 미쓰비시 타나베 파마 코퍼레이션 | 신데칸-1 및 섬유아세포 성장 인자 수용체를 표적화하는 이중특이적 결합제 |
| CA3118326A1 (en) * | 2018-10-29 | 2020-05-07 | Umc Utrecht Holding B.V. | Iga mediated killing of aberrant cells by cd47- sirpalpha checkpoint inhibition of neutrophils |
| CA3118892A1 (en) * | 2018-11-08 | 2020-05-14 | Orionis Biosciences, Inc. | Modulation of dendritic cell lineages |
| AU2019380503A1 (en) | 2018-11-14 | 2021-06-03 | Arch Oncology, Inc. | Therapeutic SIRPα antibodies |
| JP7773372B2 (ja) | 2019-03-28 | 2025-11-19 | オリオニス バイオサイエンシズ，インコーポレイテッド | 線維芽細胞活性化タンパク質結合物質およびその使用 |
| JP7689079B2 (ja) | 2019-03-28 | 2025-06-05 | オリオニス バイオサイエンシズ，インコーポレイテッド | 治療用インターフェロンアルファ１タンパク質 |
| US12351614B2 (en) | 2019-03-28 | 2025-07-08 | Orionis Biosciences, Inc. | CLEC9A-based chimeric protein complexes |
| CN118126195A (zh) * | 2019-08-30 | 2024-06-04 | 正大天晴药业集团南京顺欣制药有限公司 | 一种靶向PD-L1和TGF-β的融合蛋白及其用途 |
| WO2021062181A1 (en) * | 2019-09-26 | 2021-04-01 | Orionis Biosciences, Inc. | Conjugated chimeric proteins |
| WO2021101796A1 (en) * | 2019-11-18 | 2021-05-27 | The Brigham And Women's Hospital, Inc. | Codon optimized new generation regulatable fusogenic oncolytic herpes simplex virus type 1 virus and methods of use |
| EP4069291A1 (en) | 2019-12-03 | 2022-10-12 | Evotec International GmbH | Interferon-associated antigen binding proteins and uses thereof |
| CN113354738B (zh) * | 2020-03-05 | 2022-09-09 | 绍兴德方华生物技术有限公司 | 融合毒素VEGF165b/mGEL及其编码基因与应用 |
| BR112022021992A2 (pt) * | 2020-04-30 | 2023-01-03 | Arch Oncology Inc | Método de tratamento de câncer em um sujeito em necessidade do mesmo |
| EP4174087A4 (en) * | 2020-06-30 | 2024-08-07 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | MEDICINES FOR THE TREATMENT OF TUMORS |
| CN116194466A (zh) * | 2020-08-27 | 2023-05-30 | 联邦高等教育系统匹兹堡大学 | 编码重组转化生长因子(TGF)-β单体的溶瘤病毒及其用途 |
| CA3192236A1 (en) | 2020-09-10 | 2022-03-17 | Tony Lahoutte | Antibody fragment against fap |
| US20220196651A1 (en) * | 2020-12-06 | 2022-06-23 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
| CN114349850A (zh) * | 2020-12-18 | 2022-04-15 | 蒋庆华 | 抗体及其制备方法和编码核酸以及工程细胞 |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| AU2023264245A1 (en) | 2022-05-02 | 2024-12-19 | Precirix N.V. | Pre-targeting |
| EP4619435A1 (en) | 2022-11-16 | 2025-09-24 | Boehringer Ingelheim International GmbH | Predictive efficacy biomarkers for anti-sirpa antibodies |
| CN116732012A (zh) * | 2023-03-13 | 2023-09-12 | 山东舜丰生物科技有限公司 | 碱基编辑器及其应用 |
| EP4480501A1 (en) * | 2023-06-21 | 2024-12-25 | Nmi Naturwissenschaftliches Und Medizinisches Institut An Der Universität Tübingen | Sirp nanobodies |
| KR20260049221A (ko) * | 2023-07-29 | 2026-04-13 | 상하이 카이진 바이오테크놀로지, 리미티드 | 변형된 e형 다중특이성 항체 |
| CN117430716B (zh) * | 2023-10-16 | 2024-05-31 | 珠海臻谱基因科技有限公司 | 靶向保守的HIV gp41亚基近膜端外区的重组干扰素药物及其应用 |
Family Cites Families (159)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
| US4537776A (en) | 1983-06-21 | 1985-08-27 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| DE3853740T2 (de) | 1987-06-10 | 1995-11-09 | Dana Farber Cancer Inst Inc | Bifunktionelle Antikörperkonstruktionen und Verfahren zur selektiven Tötung von Zellbeständen. |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| JP3115318B2 (ja) | 1989-08-22 | 2000-12-04 | イミュネックス・コーポレーション | Ｇｍ―ｃｓｆ及びｉｌ―３を含む融合タンパク質 |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR970002255B1 (ko) | 1990-06-11 | 1997-02-26 | 넥스스타 파아마슈티컬드, 인크. | 핵산 리간드 |
| US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| SE9201966D0 (sv) | 1992-06-25 | 1992-06-25 | Trion Forskning & Utveckling | Interleukin-1beta deletion mutant |
| PT1621554E (pt) | 1992-08-21 | 2009-07-13 | Univ Bruxelles | Imunoglobtainas desprovidas de cadeias leves |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US5914254A (en) | 1993-08-02 | 1999-06-22 | Celtrix Pharmaceuticals, Inc. | Expression of fusion polypeptides transported out of the cytoplasm without leader sequences |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| EP0773952B1 (en) | 1994-07-20 | 2003-11-12 | The General Hospital Corporation | Interaction trap systems for detecting protein interactions |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| AU6961796A (en) | 1995-09-12 | 1997-04-01 | Chiron Corporation | Improved interleukin-6 receptor antagonist |
| EP0770397B1 (en) | 1995-10-18 | 2004-04-21 | Akzo Nobel N.V. | Newcastle disease virus combination vaccine |
| US5716946A (en) | 1996-02-13 | 1998-02-10 | Wisconsin Alumni Research Foundation | Multiple sclerosis treatment |
| US5986059A (en) | 1996-06-14 | 1999-11-16 | Bayer Corporation | T-cell selective interleukin-4 agonists |
| US6653104B2 (en) | 1996-10-17 | 2003-11-25 | Immunomedics, Inc. | Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| WO1999037681A2 (en) | 1998-01-26 | 1999-07-29 | Unilever Plc | Method for producing antibody fragments |
| AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| SI1121382T1 (sl) | 1998-10-16 | 2007-02-28 | Biogen Idec Inc | Fuzijski proteini interferona-beta in uporabe |
| DK1656952T3 (da) | 1998-10-16 | 2014-01-20 | Biogen Idec Inc | Polyalkylenglycolkonjugater af interferon beta-1A og anvendelser deraf |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| AU2291700A (en) | 1999-01-19 | 2000-08-07 | Unilever Plc | Method for producing antibody fragments |
| CA2372464C (en) | 1999-05-05 | 2012-07-31 | Phylogica Limited | Isolating biological modulators from biodiverse gene fragment libraries |
| ATE488584T1 (de) | 1999-05-26 | 2010-12-15 | Next Biomed Technologies Nbt Oy | Verfahren und materialien zur erzeugung von sh3 domänen mit angepassten bindungseigenschaften |
| MXPA02001878A (es) | 1999-08-23 | 2003-08-20 | Dana Farber Cancer Inst Inc | Moleculas b7-4 novedosas y usos de las mismas. |
| US7101974B2 (en) | 2000-03-02 | 2006-09-05 | Xencor | TNF-αvariants |
| US7696168B2 (en) | 2000-04-21 | 2010-04-13 | Tufts Medical Center, Inc. | G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same |
| US6613756B2 (en) | 2000-05-05 | 2003-09-02 | Wisconsin Alumni Research Foundation | Use of tetracycline derivatives in treating multiple sclerosis |
| SE0001877D0 (sv) | 2000-05-22 | 2000-05-22 | Klaus Mosbach | Molecular imprinting |
| US20030190598A1 (en) | 2000-05-26 | 2003-10-09 | Jasmid Tanha | Single-domain antigen-binding antibody fragments derived from llama antibodies |
| GB0014356D0 (en) | 2000-06-12 | 2000-08-02 | Colover Jack | Treatment of multiple sclerosis |
| US20020025304A1 (en) | 2000-06-16 | 2002-02-28 | Croze Edward M. | Novel interferon for the treatment of multiple sclerosis |
| JP4863150B2 (ja) | 2000-08-30 | 2012-01-25 | ザ・ペン・ステート・リサーチ・ファンデーション | インターロイキン１３のアミノ酸置換変異体 |
| JP5291279B2 (ja) | 2000-09-08 | 2013-09-18 | ウニヴェルジテート・チューリッヒ | 反復モジュールを含む反復タンパク質の集合体 |
| DE10053224A1 (de) | 2000-10-26 | 2002-05-08 | Univ Goettingen Georg August | Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien |
| EP2284270A3 (en) | 2000-12-13 | 2012-07-25 | Anaphore, Inc. | Method for the identification and isolation of binding polypeptides from combinatorial libraries of proteins having the scaffold structure of C-type lectin-like domains |
| GB0110029D0 (en) | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
| US20020193569A1 (en) | 2001-06-04 | 2002-12-19 | Idec Pharmaceuticals Corporation | Bispecific fusion protein and method of use for enhancing effector cell killing of target cells |
| BR0212256A (pt) | 2001-08-30 | 2004-08-31 | Biorexis Pharmaceutical Corp | Proteìnas de fusão de transferrina modificadas |
| US7371849B2 (en) | 2001-09-13 | 2008-05-13 | Institute For Antibodies Co., Ltd. | Methods of constructing camel antibody libraries |
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| PT1537878E (pt) | 2002-07-03 | 2010-11-18 | Ono Pharmaceutical Co | Composições de imunopotenciação |
| MXPA05003493A (es) | 2002-10-02 | 2005-09-30 | Catalyst Biosciences | Metodos para generar y seleccionar proteasas con especificidad alterada. |
| EP2284192A3 (en) | 2002-11-08 | 2011-07-20 | Ablynx N.V. | Camelidae antibodies for sublingual administration |
| GB0228210D0 (en) | 2002-12-03 | 2003-01-08 | Babraham Inst | Single chain antibodies |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| JP4490290B2 (ja) | 2002-12-31 | 2010-06-23 | ネクター セラピューティクス アラバマ，コーポレイション | 加水分解安定性マレイミド末端ポリマー |
| JP2007524348A (ja) | 2003-01-07 | 2007-08-30 | ダイアックス、コープ | クニッツドメインライブラリー |
| TW200526780A (en) | 2004-01-06 | 2005-08-16 | Hayashibara Biochem Lab | TNF antagonists and TNF inhibitors comprising the same as the active ingredient |
| US20110020273A1 (en) | 2005-04-06 | 2011-01-27 | Ibc Pharmaceuticals, Inc. | Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof |
| US20060008844A1 (en) | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
| DE102004049479A1 (de) | 2004-10-11 | 2006-04-13 | Scil Proteins Gmbh | Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie |
| EP1812038A1 (en) | 2004-11-18 | 2007-08-01 | VIB vzw | Fibronectin iii domain as leptin receptor antagonists |
| JP2008520717A (ja) | 2004-11-19 | 2008-06-19 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 多発性硬化症についての処置 |
| WO2006115800A2 (en) | 2005-04-15 | 2006-11-02 | The Regents Of The University Of California | Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| AU2006249144B2 (en) | 2005-05-18 | 2011-11-17 | Ablynx Nv | Improved NanobodiesTM against Tumor Necrosis Factor-alpha |
| GB0513047D0 (en) | 2005-06-27 | 2005-08-03 | Thermo Finnigan Llc | Electronic ion trap |
| CA2612241C (en) | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| HUE043492T2 (hu) | 2005-08-23 | 2019-08-28 | Univ Pennsylvania | Módosított nukleozidokat tartalmazó RNS és eljárások az alkalmazására |
| TW200732347A (en) | 2005-10-06 | 2007-09-01 | Trophogen Inc | VEGF analogs and methods of use |
| WO2007110231A2 (en) | 2006-03-28 | 2007-10-04 | Nautilus Biotech, S.A. | MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES |
| US20080131431A1 (en) | 2006-05-15 | 2008-06-05 | Viral Logic Systems Technology Corp. | CD47 related compositions and methods for treating immunological diseases and disorders |
| CA2693326A1 (en) | 2006-08-02 | 2008-02-07 | Mcgill University | Gm-csf and il-15 fusokines and methods for modulation of the immune response |
| EP1892248A1 (en) | 2006-08-21 | 2008-02-27 | Eidgenössische Technische Hochschule Zürich | Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase |
| AU2007331672A1 (en) | 2006-12-15 | 2008-06-19 | Ablynx N.V. | Amino acid sequences that modulate the interaction between cells of the immune system |
| US9023352B2 (en) | 2007-02-20 | 2015-05-05 | Tufts University | Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein |
| US11535673B2 (en) | 2007-04-05 | 2022-12-27 | President and Fellows of Harvard CoHege | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
| CN103897063B (zh) | 2007-06-01 | 2017-04-12 | 马里兰大学巴尔的摩分校 | 免疫球蛋白恒定区Fc受体结合剂 |
| KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| EP2173377B1 (en) | 2007-06-26 | 2017-11-29 | University of Miami | Antibody-endostatin fusion protein and its variants |
| CN101868246A (zh) | 2007-09-21 | 2010-10-20 | 加利福尼亚大学董事会 | 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性 |
| PL2492355T3 (pl) | 2007-11-29 | 2015-09-30 | Molecular Health Gmbh | Receptor erytropoetyny ochronny dla tkanki (nepor) i sposoby zastosowania |
| WO2009089149A1 (en) | 2008-01-03 | 2009-07-16 | The Johns Hopkins University | B7-h1 (cd274) antagonists induce apoptosis of tumor cells |
| PT2242512T (pt) | 2008-01-15 | 2016-07-18 | Univ Leland Stanford Junior | Métodos para manipular a fagocitose mediada por cd47 |
| RU2531758C2 (ru) | 2008-02-11 | 2014-10-27 | Куретек Лтд. | Моноклональные антитела для лечения опухолей |
| CN101525381B (zh) | 2008-03-04 | 2012-04-18 | 北京百川飞虹生物科技有限公司 | 一种重组复合干扰素及其表达载体的构建和表达 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| JP2012500652A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | 標的化共刺激ポリペプチドおよび癌を処置するための使用方法 |
| ES2545609T3 (es) | 2008-08-25 | 2015-09-14 | Amplimmune, Inc. | Composiciones de antagonistas de PD-1 y métodos de uso |
| WO2010030671A1 (en) | 2008-09-09 | 2010-03-18 | University Of Medicine And Dentistry Of New Jersey | Type i interferon antagonists |
| PL2342226T3 (pl) | 2008-09-26 | 2017-01-31 | Dana-Farber Cancer Institute, Inc. | Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania |
| WO2010036918A2 (en) | 2008-09-26 | 2010-04-01 | University Of Massachusetts | Intracellular dna receptor |
| CA2749558C (en) | 2008-12-08 | 2019-01-15 | Complix Nv | Single-chain antiparallel coiled coil proteins |
| EP4209510B1 (en) | 2008-12-09 | 2024-01-31 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| EP3192811A1 (en) | 2009-02-09 | 2017-07-19 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| US20120039806A1 (en) * | 2009-03-23 | 2012-02-16 | Mireille Hanna Lahoud | Compounds and Methods for Modulating an Immune Response |
| PE20120630A1 (es) | 2009-08-17 | 2012-05-26 | Roche Glycart Ag | Inmunoconjugados dirigidos |
| JP2013504539A (ja) | 2009-09-10 | 2013-02-07 | サイトス バイオテクノロジー アーゲー | 糖尿病治療におけるインターロイキン１βムテイン・コンジュゲートの使用 |
| NO2504364T3 (enExample) | 2009-11-24 | 2018-01-06 | ||
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| PT2542590T (pt) | 2010-03-05 | 2017-08-31 | Univ Johns Hopkins | Composições e métodos para anticorpos e proteínas de fusão imunomoduladores direcionados |
| US20110262348A1 (en) | 2010-03-29 | 2011-10-27 | Vrije Universiteit Brussel | Selective targeting of intratumoral cells |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| HUE029139T2 (hu) | 2011-02-10 | 2017-02-28 | Roche Glycart Ag | Mutáns interleukin-2 polipeptidek |
| SI2699264T1 (en) | 2011-04-20 | 2018-08-31 | Medimmune Llc | Antibodies and other molecules that bind b7-h1 and pd-1 |
| EP2718457A4 (en) | 2011-06-06 | 2014-12-24 | Immungene Inc | GENETICALLY MODIFIED FUSION MOLECULES LIGAND TNFSF-ANTIBODY ELEMENT |
| JP2014519338A (ja) * | 2011-06-16 | 2014-08-14 | ノバルティス アーゲー | 治療薬として使用される可溶性タンパク質 |
| CN102850458B (zh) | 2011-06-28 | 2014-10-01 | 华博生物医药技术（上海）有限公司 | 新型重组双功能融合蛋白及其制法和用途 |
| SE535863C2 (sv) | 2011-07-18 | 2013-01-22 | Atlas Copco Ind Tech Ab | Hållare för motordrivet verktyg innefattande klämdelar med genomgående hål |
| WO2013059885A2 (en) * | 2011-10-28 | 2013-05-02 | Cephalon Australia Pty Ltd | Polypeptide constructs and uses thereof |
| AU2013211059B8 (en) | 2012-01-20 | 2017-12-21 | Centre Hospitalier Regional Universitaire De Montpellier | Targeted mutant alpha-helical bundle cytokines |
| CA2866126A1 (en) | 2012-03-03 | 2013-09-12 | Immungene, Inc. | Engineered antibody-interferon mutant fusion molecules |
| AU2013263076B2 (en) | 2012-05-15 | 2017-08-31 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| HRP20192013T1 (hr) | 2012-12-17 | 2020-02-07 | Trillium Therapeutics Inc. | Liječenje cd47+ oboljelih stanica sa sirp alfa-fc fuzijama |
| JP6815196B2 (ja) | 2013-03-13 | 2021-01-20 | イマジナブ、 インコーポレイテッド | Ｃｄ８に対する抗原結合性構築物 |
| US10093745B2 (en) * | 2013-05-29 | 2018-10-09 | The Regents Of The University Of California | Anti-CSPG4 fusions with interferon for the treatment of malignancy |
| MX375441B (es) | 2013-07-18 | 2025-03-06 | Vib Vzw | Fusocinas que implican citocinas con una afinidad de union al receptor considerablemente menor. |
| DK3022226T3 (en) | 2013-07-19 | 2019-03-25 | Vib Vzw | TARGETED MODIFIED IL-1 FAMILY MEMBERS |
| AU2014291961B2 (en) | 2013-07-19 | 2018-09-27 | Centre Hospitalier Regional Universitaire De Montpellier | Targeted modified TNF family members |
| US9732135B2 (en) | 2013-07-19 | 2017-08-15 | Vib Vzw | Targeting of human interferon antagonists |
| CA2935423C (en) | 2014-01-24 | 2023-11-07 | Dana-Farber Cancer Institute, Inc. | Antibody molecules to pd-1 and uses thereof |
| WO2015138600A2 (en) * | 2014-03-11 | 2015-09-17 | The Board Of Trustees Of The Leland Stanford Junior University | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies |
| CN106459218B (zh) | 2014-03-24 | 2021-03-02 | 宜明昂科生物医药技术（上海）有限公司 | 新的重组双功能融合蛋白、其制剂和用途 |
| UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
| WO2016002263A1 (ja) | 2014-06-30 | 2016-01-07 | ソニー株式会社 | 無線通信装置、無線通信方法及びプログラム |
| CN106462263B (zh) | 2014-07-11 | 2020-07-17 | 株式会社和冠 | 位置指示器、位置检测装置以及位置检测装置的输入控制方法 |
| JP6909153B2 (ja) | 2014-08-05 | 2021-07-28 | アポロミクス インコーポレイテッド | 抗ｐｄ−ｌ１抗体 |
| WO2016023040A1 (en) | 2014-08-08 | 2016-02-11 | Alexo Therapeutics International | Sirp-alpha variant constructs and uses thereof |
| SI3482766T1 (sl) | 2014-08-11 | 2020-09-30 | Delinia, Inc. | Spremenjene variante IL-2, ki selektivno aktivirajo regulatorne T celice za zdravljenje avtoimunskih bolezni |
| EP2990416B1 (en) * | 2014-08-29 | 2018-06-20 | GEMoaB Monoclonals GmbH | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
| WO2016061142A1 (en) | 2014-10-14 | 2016-04-21 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| ES2727154T3 (es) | 2014-10-24 | 2019-10-14 | Astrazeneca Ab | Combinación |
| GB201500461D0 (en) | 2015-01-12 | 2015-02-25 | Cresendo Biolog Ltd | Therapeutic molecules |
| GB201500463D0 (en) | 2015-01-12 | 2015-02-25 | Cresendo Biolog Ltd | Therapeutic molecules |
| US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| MA41460A (fr) | 2015-02-03 | 2017-12-12 | Oncomed Pharm Inc | Agents de liaison à la tnfrsf et leurs utilisations |
| KR20170109582A (ko) | 2015-02-06 | 2017-09-29 | 히트 바이오로직스, 인코퍼레이티드 | 벡터 공동 발현 백신 및 공동 자극 분자 |
| WO2016166139A1 (en) | 2015-04-14 | 2016-10-20 | Eberhard Karls Universität Tübingen | Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells |
| US9845345B2 (en) | 2015-05-18 | 2017-12-19 | Ab Initio Biotherapeutics, Inc. | SIRP polypeptide compositions and methods of use |
| WO2016201251A1 (en) * | 2015-06-12 | 2016-12-15 | Immungene, Inc. | Focused interferon immunotherapy for treatment of cancer |
| WO2017027422A1 (en) | 2015-08-07 | 2017-02-16 | Alexo Therapeutics Inc. | Constructs having a sirp-alpha domain or variant thereof |
| WO2017077382A1 (en) | 2015-11-06 | 2017-05-11 | Orionis Biosciences Nv | Bi-functional chimeric proteins and uses thereof |
| CN116769054A (zh) | 2016-02-05 | 2023-09-19 | 奥里尼斯生物科学私人有限公司 | 双特异性信号传导剂及其用途 |
| US11753463B2 (en) | 2016-05-13 | 2023-09-12 | Orionis Biosciences BV | Therapeutic targeting of non-cellular structures |
| US11236141B2 (en) | 2016-05-13 | 2022-02-01 | Orionis Biosciences BV | Targeted mutant interferon-beta and uses thereof |
| WO2018075960A1 (en) | 2016-10-21 | 2018-04-26 | Tioma Therapeutics, Inc. | Therapeutic cd47 antibodies |
| CN110325549B (zh) * | 2016-12-09 | 2024-03-08 | 艾利妥 | 抗SIRPα抗体及其使用方法 |
| CN110573172A (zh) | 2017-02-06 | 2019-12-13 | 奥里尼斯生物科学有限公司 | 靶向的工程化干扰素及其用途 |
| MX2019009255A (es) * | 2017-02-06 | 2019-11-05 | Orionis Biosciences Nv | Proteínas quiméricas dirigidas y sus usos. |
| WO2018146074A1 (en) | 2017-02-07 | 2018-08-16 | Vib Vzw | Immune-cell targeted bispecific chimeric proteins and uses thereof |
| US20210024631A1 (en) * | 2018-03-28 | 2021-01-28 | Orionis Biosciences, Inc. | Bi-functional proteins and construction thereof |
| US12084497B2 (en) * | 2018-08-08 | 2024-09-10 | Orionis Biosciences, Inc. | SIRP1α targeted chimeric proteins and uses thereof |
-
2018
- 2018-02-05 MX MX2019009255A patent/MX2019009255A/es unknown
- 2018-02-05 IL IL268346A patent/IL268346B2/en unknown
- 2018-02-05 EP EP18706967.9A patent/EP3577133A1/en active Pending
- 2018-02-05 JP JP2019563679A patent/JP7476467B2/ja active Active
- 2018-02-05 KR KR1020197024342A patent/KR102642385B1/ko active Active
- 2018-02-05 CA CA3052523A patent/CA3052523A1/en active Pending
- 2018-02-05 AU AU2018216032A patent/AU2018216032B2/en active Active
- 2018-02-05 CN CN201880023712.1A patent/CN110546160A/zh active Pending
- 2018-02-05 US US16/483,114 patent/US11384154B2/en active Active
- 2018-02-05 WO PCT/EP2018/052814 patent/WO2018141964A1/en not_active Ceased
-
2022
- 2022-05-16 US US17/745,307 patent/US20220281992A1/en active Pending
- 2022-10-14 JP JP2022165861A patent/JP7605800B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020505955A5 (enExample) | ||
| JP7291196B2 (ja) | 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体 | |
| JP2020530299A5 (enExample) | ||
| JP2020530298A5 (enExample) | ||
| CN113260630B (zh) | 用于用抗cd123免疫治疗来治疗癌症的组合物和方法 | |
| ES2784261T3 (es) | Receptores de células T anti-KRAS mutado | |
| CN109843922B (zh) | 用DuoCAR治疗癌症的组合物和方法 | |
| JP6821688B2 (ja) | キメラ抗原受容体および使用方法 | |
| JP6901493B2 (ja) | 抗ｂｃｍａポリペプチド及びタンパク質 | |
| ES2875057T3 (es) | Anticuerpos anti-CD276 (B7H3) | |
| ES2973064T3 (es) | Receptores de células T frente al virus del papiloma humano 16 E6 | |
| JP2023509323A5 (enExample) | ||
| US20180346544A1 (en) | Anti-cd276 chimeric antigen receptors | |
| Deng et al. | Novel recombinant immunotoxin of EGFR specific nanobody fused with cucurmosin, construction and antitumor efficiency in vitro | |
| US20140080766A1 (en) | Compositions and methods for macromolecular drug delivery | |
| KR20190034630A (ko) | 암 치료를 위한 변형된 항체-알부민 나노입자 복합체 | |
| Wang et al. | Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy | |
| CN108463469B (zh) | 一种与抗可替宁抗体连接的嵌合抗原受体及其用途 | |
| JP2021534757A5 (enExample) | ||
| US20160333422A1 (en) | Anti-ny-br-1 polypeptides, proteins, and chimeric antigen receptors | |
| CN103965363A (zh) | 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途 | |
| CN113412119A (zh) | 用于用抗cd38免疫治疗来治疗癌症的组合物和方法 | |
| US20180244745A1 (en) | Epha3 and multi-valent targeting of tumors | |
| JP2023546725A5 (enExample) | ||
| WO2016058148A1 (zh) | 抗butyrophilin-3人源化抗体及其使用 |